Brief: Biosergen Provides Phase 2 Clinical Development Strategy Update

Biosergen AB

29/03/2023 07:48

March 29 (Reuters) - Biosergen AB  BIOSGN.ST :
    * BIOSERGEN PROVIDES PHASE 2 CLINICAL DEVELOPMENT STRATEGY
UPDATE
    * BASED ON DATA FROM COMPLETED PHASE I TRIAL, CO WILL
INITIATE A
PHASE 2 TRIAL TO SHOW BSG005'S POTENTIAL TO CHALLENGE
AMPHOTERICIN B'S ROLE AS A LAST RESORT ANTIFUNGAL TREATMENT, AS
WELL AS TO DE-RISK FURTHER DEVELOPMENT PATH OF BSG005
    * PLANS TO INITIATE ITS FIRST PHASE 2 CLINICAL TRIAL TOWARDS
END
OF Q2 2023
    * A TOP-LINE DATA READOUT IS EXPECTED APPROXIMATELY SIX
MONTHS
AFTER DOSING OF FIRST PATIENT, EXPECTED IN EARLY Q3 2023

Source text for Eikon:  ID:nWkr79kM1K 
Further company coverage:  BIOSGN.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))